Co-injection of TIE2-expressing macrophages with tumor cells significantly enhanced angiogenesis (93), while therapeutic targeting of TIE2 resulted in tumor vasculature regression and inhibited the progression of late-stage, metastatic mammary tumors, and pancreatic carcinomas (94). The gene discussed is TEK; the disease is neoplasm.